CASE REPORT

Anti-TNF-α and hydralazine drug-induced lupus

Maria Vitória Quaresma¹
Fernanda Brandão de Oliveira¹
Maria Fernanda Reis Gavazzoni Dias¹

Fred Bernardes Filho¹
Mercedes Prates Pockstaller¹
David Rubem Azulay¹

INTRODUCTION

Drug-induced lupus (DIL) was first reported in 1945 by Hoffman and it is estimated that over 10% of the cases of systemic lupus erythematosus (SLE) are drug-induced. ¹,² Although the pathogenesis is not completely understood, genetic predisposition plays an important role.³,⁴ There is evidence of greater association in slow, acetylating patients, in which there is a genetically-mediated reduction of the synthesis of N-acetyltransferase. The anti-histone antibodies are considered markers of DIL.⁵

The clinical presentation is of insidious onset and can be similar to that of SLE, chronic or subacute cutaneous lupus erythematosus.²,⁶ The most common symptoms are arthralgia and arthritis, sudden erythema and polycyclic lesions located in sun-exposed areas, similar to the presentation of subacute lupus erythematosus. Severe systemic involvement is rare, with fewer occurrences of alterations in the central nervous, renal, and hematopoietic systems.⁴,⁷

Recently, with the introduction of new drugs in clinical practice, an increase in the number of illness-triggering implicated drugs has been reported, with special emphasis on anti-TNF-α drugs. In the up-to-date list, almost one hundred medications have been associated with the occurrence of drug-induced lupus. The authors present two case reports of the illness induced respectively by hydralazine and infliximab, addressing the clinical and laboratorial characteristics, diagnosis, and treatment.

Keywords: Acetyl-CoA C-Acetyltransferase; Acetylation; Autoimmunity; Hydralazine; Lupus erythematosus, cutaneous; Tumor necrosis factor-alpha

Abstract: Drug-induced lupus is a rare drug reaction featuring the same symptoms as idiopathic lupus erythematous. Recently, with the introduction of new medicines in clinical practice, an increase in the number of illness-triggering implicated drugs has been reported, with special emphasis on anti-TNF-α drugs. In the up-to-date list, almost one hundred medications have been associated with the occurrence of drug-induced lupus. The authors present two case reports of the illness induced respectively by hydralazine and infliximab, addressing the clinical and laboratorial characteristics, diagnosis, and treatment.
medications to control symptoms, such as anti-inflammatory drugs (NSAIDs), can be indicated. In extensive or refractory cases, systemic corticosteroid may be employed until clinical symptoms resolve.7,9

This paper presents two cases of hydralazine- and infliximab-induced lupus with clinical and histopathologic features. The authors suggest that the two conditions are different based on distinct pathogenesis.

**CASE REPORT**

Case 1: A 54-year-old male patient with hypertension, taking hydralazine for four years, had been presenting erythematous, scaly and edematous papules on the trunk, back, upper limbs and sun-exposed areas for the last two months (Figure 1). Laboratory tests: ANA 1:640 homogeneous nuclear pattern and positive anti-histone. Histopathology was compatible with lupus erythematosus (Figure 2). Hydralazine was discontinued and prednisone was prescribed. There was rapid improvement of skin lesions, and resolution of symptoms after 4 weeks (Figure 3).

Case 2: A 37-year-old male patient, bearer of ulcerative colitis, started on infliximab at a dose of 5 mg/kg. After a two-month therapy he presented erythematous, brownish, infiltrated, rough surface lesions on the face and ear lobes (Figure 4). Laboratory
FIGURE 3: Drug-induced lupus by hydralazine. Fig. (A, B): There was rapid improvement of skin lesions. Fig. (C, D): Resolution of symptoms after 4 weeks of drug discontinuation.

FIGURE 4: Drug-induced lupus by anti-TNF-α. Fig. 4 (A): Erythematous, brownish, infiltrated, rough surface lesions on the face. Figure 4 (B): The same pattern involving preauricular and ear lobes.
FIGURE 5: Drug-induced lupus by anti-TNF-α. Fig. (A, B, C). Histopathology: follicular hyperkeratosis, vacuolization of the basal layer of the epidermal and follicular epithelium, superficial perivascular mononuclear infiltrate and melanophages in the papillary dermis.

Histopathology was compatible with lupus erythematosus (Figure 5).

DISCUSSION

Drugs associated with induction of lupus erythematosus are classified into groups according to the level of available scientific evidence of causal relationship, and hydralazine is definitely regarded as a drug capable of inducing lupus (controlled studies). Anti-TNF-α therapies are drugs that have recently been reported in the induction of the disease. The mechanisms that induce lupus with the use of hydralazine and anti-TNF-α therapies are distinct.

Hydralazine is metabolized by the liver through acetylation by the enzyme N-acetyltransferase. The rate of acetylation is genetically determined, and the slow or fast acetylator phenotype is controlled by a single, recessive gene associated with low activity of hepatic acetyltransferase. Since the elimination of hydralazine depends mainly on acetylation, acetylator individuals may exhibit toxic and/or immunological effects, such as DIL related to drug accumulation. Hydralazine also inhibits T-cell DNA methylation, which has the function of deleting non-essential or potentially deleterious-to-cell-function genes, and induces self-reactivity in these cells, resulting in autoimmunity.

Infliximab is a chimeric, human-murine, monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF-α. The development of lupus erythematosus during anti-TNF-α therapy is unclear, though three mechanisms have been proposed. The first is that anti-TNF-α inhibits Th1 cytokine production, increasing the production of Th2 cytokines, leading to the production of autoantibodies and a lupus-like syndrome. Another hypothesis assumes that systemic inhibition of TNF-α might interfere with apoptosis, affecting the clearance of nuclear debris and apoptotic neutrophils by phagocytes, thus promoting the production of autoantibodies to DNA and other nuclear antigens. In the third hypothesis, the anti-TNF-α therapy could inhibit cytotoxic T cells, reducing the elimination of autoantibodies produced by B-cells.

Due to the difficulties encountered in diagnosis, some criteria were proposed for guidance and the patient in case 1 presented enough features to be diagnosed with DIL: continuous use of the drug for at least 60 days; sudden and persistent erythema; positive anti-histone antibodies and ANA with titers above 1/160 and disappearance of the lesions and symptoms after at least two weeks of drug discontinuation. In addition, the patient’s histopathology was compatible with lupus erythematosus.

Certain characteristics aid in the diagnosis of anti-TNF-α-induced lupus: onset of symptoms time-related to the use of anti-TNF-α therapy, at least one positive serology (ANA, anti-DS-DNA) and one non-serological criterion (arthritis, serositis, hematological disorders - anemia, leukopenia and thrombocytopenia - or malar rash). In case 2, the patient had the 3 main characteristics listed above (onset of symptoms, positive serology and malar rash), in addition to typical histopathological features of lupus erythematosus.

Histopathological findings of lupus erythematosus aid in the diagnosis but are not mentioned among the criteria for defining classic DIL or anti-TNF-α drug-induced lupus.
The suspension of anti-TNF-α therapy is controversial in asymptomatic patients with positive ANA. Systemic corticosteroids were not initiated in case 2 due to the benignity of the clinical presentation. Both patients showed clinical improvement during follow-up.

The recognition of the fact that the condition is drug-induced avoids unnecessary investigations and enables appropriate management of the patient. More studies are necessary to better elucidate the pathogenesis of anti-TNF-induced lupus.

REFERENCES
1. Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Physiol. 1945;51:90-2.
2. Mota LMH, Haddad OP, Lima FAC, Carvalho JT, Mincio-Junqueira M, Neta LLS, Lima FAC. Drug-induced lupus - from basic to applied immunology. Rev Bras Reumatol. 2007;47:407-17.
3. Bohta EF, Latour LC, Brucato AJ, Kaysner C, Silva NFk, Zinzenem AF. Consensus of Systemic Lupus Erythematosus. Rev Bras Reumatol. 2006;46:196-207.
4. Petri M, Oti C, Alarcón GS, Gordon C, Mowafi J, Fritschi PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2077-86.
5. Azari F, Manzana MG, Sara-Pulver P, Dardenne M. Drug-induced lupus erythematosus. Reumatologia. 2003;54:147-54.
6. Sara-Pulver P, Azari F, Capasso E, Lubrano E, Delia A. Drug-induced lupus erythematosus. Autoimmunity. 2005;36:507-16.
7. Duarte AA, César da Silva RR, da Rocha AS, Petri M. Consensus criterios para diagnóstico de Lupus Eritematoso Sistêmico. Rev Bras Reumatol. 2012.
8. Alexander K, Ayala-G, Ahyajeh H, Ahmed A. Lupus Nodules. In: Alexander G, Ed. Arthritis and Rheuma. 6th ed. London: Blackwell; 2008. p. 271-7.
9. Wolter DA, Dorio MD. Lupus-like syndromes attributed to anti-TNF-α monoclonal antibody therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84:979-84.
10. Azulay RD, Azulay DR. Osteoarticosis sobrepostas de Interesses Dermatológico e Reumatológico. In: Azulay RD, Azulay DR, Editor. Dermatologia. 6 ed. Rio de Janeiro: Guanabara Koogan; 2014. p. 778-81.